Algorithmic Oncogenomic Transition Safety in Closed-Loop Biological Dosing Systems: Formal Closure of the Dual PTEN/MAPK Vulnerability Across 250 NCI GDC/TCGA Patients

AETERNA Clinical & Computational Biology Monograph I (2026) Author: Dimitar Stavrev Prodromov (ORCID 0009-0004-8070-1348), AETERNA Technologies EOOD / AETERNA Research Laboratories, Pomorie, Bulgaria (EC PIC 865986222) Authority: 0x41_45_54_45_52_4e_41_5f_4c_4f_47_4f_53_5f_44_49_4d_49_54_41_52_5f_50_52_4f_44_52_4f_4d_56_21 Abstract & Breakthrough: Formalizes the deterministic O(1) TRANSITION_SAFETY algebraic gate of the AETERNA Selye Engine operating over an 87-locus binary somatic vector (𝔽264 × 𝔽223). Identifies and formally closes the dual PTEN loss-of-function + MAPK/RAS hyperactivation senescence-evasion vulnerability under wild-type TP53 via the disjunctive lock Glock(g) = I[TP53 ∨ (PTEN ∧ MAPK)], paired with renal GFR < 30.0 mL/min halt clamping, mass scaling, ApoE4 attenuation (α ∈ {1.00, 0.80, 0.60}), and Michaelis–Menten telomerase shutdown. Validated across 250 real NCI GDC/TCGA patient profiles (n = 50 each from TCGA-BRCA, TCGA-GBM, TCGA-LAML, TCGA-LUAD, TCGA-PAAD), achieving 100.00% recall and 100.00% specificity (67/67 locked to 0.0 mg telomerase induction; locked cohort mortality 61.19% vs. unlocked 55.74%). Sovereign License Notice (CC BY-NC-ND 4.0 + PSRL v2.0): Zero source code is disclosed. All mathematical operators, Boolean gating topologies, pharmacokinetic scaling laws, and clinical proofs are protected strictly under CC BY-NC-ND 4.0 and the Proprietary Sovereign Research License (PSRL v2.0). Commercial exploitation, clinical dosing deployment, patent/utility model filing, derivative symbol renaming, and AI/ML/LLM training or dataset distillation (EU AI Act Art. 53(1)(c), Directive (EU) 2019/790 Art. 4(3)) are strictly prohibited worldwide without a bilaterally executed notarized deed. Exclusive Jurisdiction: District Court of Burgas / WIPO Geneva.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-13
DOI
https://doi.org/10.5281/zenodo.24199982
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Algorithmic Oncogenomic Transition Safety in Closed-Loop Biological Dosing Systems: Formal Closure of the Dual PTEN/MAPK Vulnerability Across 250 NCI GDC/TCGA Patients

Dimitar Stavrev Prodromov
3 links
Zenodo (CERN European Organization for Nuclear Research)
Cancer Genomics and Diagnostics
article

Algorithmic Oncogenomic Transition Safety in Closed-Loop Biological Dosing Systems: Formal Closure of the Dual PTEN/MAPK Vulnerability Across 250 NCI GDC/TCGA Patients

Dimitar Stavrev Prodromov
article en

Abstract

AETERNA Clinical & Computational Biology Monograph I (2026) Author: Dimitar Stavrev Prodromov (ORCID 0009-0004-8070-1348), AETERNA Technologies EOOD / AETERNA Research Laboratories, Pomorie, Bulgaria (EC PIC 865986222) Authority: 0x41_45_54_45_52_4e_41_5f_4c_4f_47_4f_53_5f_44_49_4d_49_54_41_52_5f_50_52_4f_44_52_4f_4d_56_21 Abstract & Breakthrough: Formalizes the deterministic O(1) TRANSITION_SAFETY algebraic gate of the AETERNA Selye Engine operating over an 87-locus binary somatic vector (𝔽264 × 𝔽223). Identifies and formally closes the dual PTEN loss-of-function + MAPK/RAS hyperactivation senescence-evasion vulnerability under wild-type TP53 via the disjunctive lock Glock(g) = I[TP53 ∨ (PTEN ∧ MAPK)], paired with renal GFR < 30.0 mL/min halt clamping, mass scaling, ApoE4 attenuation (α ∈ {1.00, 0.80, 0.60}), and Michaelis–Menten telomerase shutdown. Validated across 250 real NCI GDC/TCGA patient profiles (n = 50 each from TCGA-BRCA, TCGA-GBM, TCGA-LAML, TCGA-LUAD, TCGA-PAAD), achieving 100.00% recall and 100.00% specificity (67/67 locked to 0.0 mg telomerase induction; locked cohort mortality 61.19% vs. unlocked 55.74%). Sovereign License Notice (CC BY-NC-ND 4.0 + PSRL v2.0): Zero source code is disclosed. All mathematical operators, Boolean gating topologies, pharmacokinetic scaling laws, and clinical proofs are protected strictly under CC BY-NC-ND 4.0 and the Proprietary Sovereign Research License (PSRL v2.0). Commercial exploitation, clinical dosing deployment, patent/utility model filing, derivative symbol renaming, and AI/ML/LLM training or dataset distillation (EU AI Act Art. 53(1)(c), Directive (EU) 2019/790 Art. 4(3)) are strictly prohibited worldwide without a bilaterally executed notarized deed. Exclusive Jurisdiction: District Court of Burgas / WIPO Geneva.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon